Cargando…
Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is deficient in th...
Autores principales: | Hayat, Amir, Haria, Dhiren, Salifu, Moro O |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769266/ https://www.ncbi.nlm.nih.gov/pubmed/19920963 |
Ejemplares similares
-
Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
por: Hanna, Ramy M., et al.
Publicado: (2020) -
Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021) -
“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
por: Ashraf, Bilal, et al.
Publicado: (2021) -
Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease
por: Beach, Lauren B., et al.
Publicado: (2016) -
An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients
por: Sonia, Shamsun Nahar, et al.
Publicado: (2023)